• 中文版
  • Home
  • About Us
    • Contract Research Organization
    • Contract Development and Manufacturing Organization
    • Accolades
    • Publications
  • Services Overview
  • Discovery Chemistry
    • Synthetic Chemistry
    • Medicinal Chemistry
    • Library Chemistry
    • Peptide Chemistry
    • Fragment Based Screening
    • Computer Aided Drug Design
    • Analytical Services
    • Protein Structure
  • Biology & Pharmacology
    • Oncology
    • Pathology Core Facility
    • Immunology
    • Tumor Immunology
    • Neuroscience
    • Cell Biology
    • In Vitro Biology
    • Metabolic & Cardiovascular Diseases
    • Epigenetics
  • Biologics Discovery
    • Antibody Discovery
    • Protein Science
    • Biologics Analytical Services
    • B Cell Cloning
  • DMPK / Exploratory Toxicology
    • DMPK / Exploratory Toxicology
    • Biomarkers, Preclinical & Clinical Sample Bioanalysis
    • Large molecule PK/BA services
  • Biologics CMC
    • Stable Cell Line Development
    • Process Development
    • Formulation Development
    • Aseptic Filling and Freeze-drying
    • Drug Developability / Manufacturability study
    • Final Container Extractables & Leachables Study
    • Analytical Development and Testing
    • GMP Production
  • Small Molecule CMC
    • Process R&D Services
    • Process Safety
    • Analytical Development
    • Pre-Formulation Development
    • Formulation Development
    • ICH Stability Studies
    • CMC CTD Support
    • Manufacturing
  • Blog
  • Careers
  • News & Events
  • Contact Us
  • Download Center

Call us today! +86 21 5132 0088

contact@chempartner.com
中文版
Shanghai ChemPartner Shanghai ChemPartner Shanghai ChemPartnerShanghai ChemPartner
  • Home
  • About Us
    • About ChemPartner
    • CRO
    • CDMO
    • Accolades
    • Publications
  • Services
    • Discovery Chemistry
      • Synthetic Chemistry
      • Medicinal Chemistry
      • Library Chemistry
      • Peptide Chemistry
      • Fragment Based Screening
      • Computer Aided Drug Design
      • Analytical Services
      • Protein Structure
    • Biology & Pharmacology
      • Oncology
      • Pathology Core Facility
      • Immunology
      • Tumor Immunology
      • Cell Biology
      • In Vitro Biology
      • Neuroscience
      • Metabolic & Cardiovascular Diseases
      • Epigenetics
    • Biologics Discovery
      • Antibody Discovery
      • Protein Science
      • Biologics Analytical Services
      • B Cell Cloning
    • DMPK / Exploratory Toxicology
      • DMPK / Exploratory Toxicology
      • Biomarkers, Preclinical & Clinical Sample Bioanalysis
      • Large molecule PK/BA services
    • Biologics CMC
      • Stable Cell Line Development
      • Process Development
      • Formulation Development
      • Aseptic Filling and Freeze-drying
      • Drug Developability / Manufacturability study
      • Final Container Extractables & Leachables Study
      • Analytical Development and Testing
      • GMP Production
    • Small Molecule CMC
      • Process R&D Services
      • Process Safety
      • Analytical Development
      • Pre-Formulation Development
      • Formulation Development
      • ICH Stability Studies
      • CMC CTD Support
      • Manufacturing
  • Blog
  • Careers
  • News & Events
  • Contact Us
  • Download Center
ChemPartner Announces its Expansion into Peptide Chemistry

ChemPartner Announces its Expansion into Peptide Chemistry

1月 8, 2016 | Press Release |

ShangPharma inks an Important Collaboration with Investment in Circle Pharma

SAN FRANCISCO, Jan. 7, 2016 /PRNewswire/ — ChemPartner is delighted to announce the expansion of its extensive CRO service offerings into peptide chemistry. This comes along with a significant investment in personnel and infrastructure, including the purchase of parallel peptide synthesis equipment and the hiring of a highly qualified peptide leader based at its new South San Francisco laboratory facility. Through this new initiative ChemPartner is able to be a true partner in therapeutic peptide drug discovery and in partnership with its other functional areas including biology, pharmacology and DMPK, ChemPartner will be able to offer a fully integrated solution in this space.

The company’s commitment to this scientific area as well as its continued focus on innovation and technology partnerships has also been excitingly cemented by a collaboration recently agreed between Circle Pharma and ShangPharma, ChemPartner’s parent company. Circle Pharma has a state of the art technology for the design and synthesis of cell permeable macrocyclic peptides which has the potential to lead to many new and innovative therapeutics, especially in the area of intracellular protein-protein interactions (PPIs). ShangPharma has made an investment in Circle and is also hosting its expansion by sharing its South San Francisco site with this innovative company. The peptide chemists at both Circle and ChemPartner will work together to develop techniques in macrocycle synthesis and ChemPartner will also provide support from its research powerhouse in Shanghai.

Michael Hui, CEO of ShangPharma said “The deal with Circle is an example of our continuing efforts to help new companies with exciting technologies in the life science space be successful. We are really excited about their plans and hope to be able to work with them in multiple different ways in the coming months as they mature and grow.”

About Circle Pharma
Founded by renowned computational chemist Prof. Matthew Jacobson (UC San Francisco) and peptide chemist Prof. Scott Lokey (UC Santa Cruz), and seed funded by Pfizer and Mission Bay Capital in 2014, Circle Pharma is developing a new paradigm for macrocycle drug discovery. Circle’s technology facilitates the design and synthesis of intrinsically cell-permeable macrocycles that can address both intra- and extra-cellular therapeutic targets, and can be delivered by oral administration. Circle’s macrocycle development platform is applicable across a wide range of serious diseases; the company is initially focusing its internal development efforts on intracellular protein-protein interactions that are key drivers in cancer.

To learn more about Circle, please visit www.circlepharma.com, contact info@circlepharma.com or call +1.650.392.0363.

About ShangPharma
ShangPharma is comprised of a family of companies including ChemPartner, ShangPharma Technology, China Gateway Biologics, China Gateway Pharmaceutical Development, and ShangPharma Investment. The group is actively investing, licensing, and forming partnerships to better serve the healthcare industry. ShangPharma aims, through all its divisions, to create an ecosystem that allows close interaction between major hospitals and academic centers, by matching them with pharmas, biotech, and research institutes to enable the success of all.

About ChemPartner
ChemPartner is a leading contract research organization providing high-quality and cost-effective services for the global pharmaceutical and biotechnology industry. The company offers a broad range of integrated services across the drug discovery and development process. ChemPartner’s services consist of discovery biologics, discovery chemistry, discovery biology and preclinical development.

For more information about ShangPharma and its subsidiaries, visit www.ShangPharma.com.

CONTACT: Ms. Jin Qin, Building 5, 998 Halei Road, Zhangjiang Hi-tech Park, Pudong,Shanghai, China, 201203, +86-21-5132-0220, jqin@shangpharma.com

Tags: ChemPartner
0
Share

You also might be interested in

Dr. Lilly Xu joins ChemPartner as Vice President and Head of DMPK and Exploratory Toxicology

6月 28, 2017

Shanghai, [...]

ChemPartner will be attending World ADC at San Diego USA.

ChemPartner will be attending World ADC at San Diego USA.

10月 12, 2015

19-22 Oct.[...]

ChemPartner Announces Opening of San Francisco Research Facility

ChemPartner Announces Opening of San Francisco Research Facility

2月 4, 2015

New facili[...]

Latest News

Shanghai ChemPartner was awarded “TOP 10 CMOs in 2019”

Shanghai ChemPartner was awarded “TOP 10 CMOs in 2019”

07/19/2019

Contract manufacturers play a significant role when it ...

Dr. Teddy Yang appointed to Vice President and Head of Biologics Discovery at Shanghai ChemPartner

03/29/2019

Shanghai, China(Mar 28, 2019) – Shanghai ChemPartner to...

ChemPartner Will Participate in BIO-Europe Spring in Vienna, Austria in March 2019

03/18/2019

Shanghai, China (March X, 2019) – March 25-27, 2019, Ch...

ChemPartner will be at the Boulder Peptide Symposium 2018

ChemPartner will be at the Boulder Peptide Symposium 2018

09/25/2018

ChemPartner, a leader in Peptide Synthesis and Developm...

Shanghai  ChemPartner  Announces Merger Deal Closure with Quantum

Shanghai ChemPartner Announces Merger Deal Closure with Quantum

08/16/2018

SHANGHAI, Aug. 16, 2018 /PRNewswire/ — Shanghai  ...

Berkeley Lights and ChemPartner Collaborate on Accelerating Antibody Discovery

06/28/2018

EMERYVILLE, Calif., June 27, 2018 /PRNewswire/ — Berkel...

Tag Cloud

2017 AACR Agreement Antibody Engineering art Berkeley Lights Best Life Science BIOtech Blend Boston Capital Market Chemistry ChemPartner Congratulates CPhI CPSA Shanghai 2016 CRO DMPK Exploratory Toxicology Labs layout Merger Deal PEGS PEGS CHINA Peptide Pharma Pharmacology product PTF Qidong Quantum Hi-Tech China Biological Research Facility San Diego San Francisco Shanghai Shanghai ChemPartner ShangPharma Sponsor Strategic Corporate Restructuring Tarveda Therapeutic Top 10 CMOs Vice President World ADC

Give us a Message

You can leave us a message by quick contact box and we'll get back to you, asap. Thanks!

Send Message

Logo

ChemPartner is a leading research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry.

Get started today.

Contact Us
  • ChemPartner Co., Ltd.
  • 1F & 3F, Block A, 2829 JinKe Road, Zhangjiang Hi-Tech Park, PuDong New Area, Shanghai China, 201203
  • +86 21 5132 0088
  • contact@chempartner.com

© 2019 — Shanghai ChemPartner Co., Ltd. All Rights Reserved  About Us  Careers  Contact Us  Privacy Policy  Sitemap

  • Home
  • Contact
  • Buy Highend
Prev Next